GLP-1 Drugs Cut Stage 4 Cancer Progression by Up to 50% in Cleveland Clinic Study
Updated
Updated · Fox News · May 26
GLP-1 Drugs Cut Stage 4 Cancer Progression by Up to 50% in Cleveland Clinic Study
5 articles · Updated · Fox News · May 26
12,112 patients in a Cleveland Clinic retrospective study showed significantly lower progression to stage 4 disease with GLP-1 drugs than with DPP-4 inhibitors in four obesity-related cancers.
Risk reduction was largest in non-small cell lung cancer at 50%, followed by breast cancer at 43%, liver cancer at 38% and colorectal cancer at 31%.
Tumors with higher GLP-1 receptor levels were also tied to better survival, with those patients about one-third less likely to die during the study period; side-effect rates were similar between the two drug groups.
The findings, due to be presented at next week's ASCO meeting in Chicago, are preliminary because the study was observational and not peer-reviewed, so it cannot prove GLP-1 drugs directly slowed cancer spread.
If new data shows GLP-1s slow tumor growth, why do some experts advise against their use during chemotherapy?
Is this popular weight-loss drug a secret weapon against cancer, or is its benefit just a side effect of shedding pounds?
GLP-1 Drugs and Cancer: Emerging Evidence, Mechanisms, and the Urgent Need for Randomized Trials
Overview
Recent research highlights that GLP-1 receptor agonist drugs may slow cancer progression, not just by improving diabetes or obesity, but through direct effects on cancer itself. This marks a significant shift in understanding and has led to calls for more investigation into their broader therapeutic uses. GLP-1 drugs may help fight cancer by reducing inflammation, which often drives tumor growth, altering tumor cell metabolism, and boosting the immune system’s ability to target cancer. These findings suggest new possibilities for cancer treatment and prevention, but further studies are needed to confirm their full potential.